Vivos Therapeutics (VVOS) Cash & Equivalents (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Cash & Equivalents data on file, last reported at $2.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 10.33% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 10.33% YoY) and the FY2025 annual result came in at $2.0 million, down 67.59% from the prior year.
• Cash & Equivalents grew to $2.1 million in Q1 2026 per VVOS's latest filing, from $2.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $17.8 million in Q1 2022 and bottomed at $1.0 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $3.9 million (2023), against an average of $5.3 million.
• The widest annual swing landed in 2022, when Cash & Equivalents tumbled 85.34%; it then surged 531.1% in 2024.
• Tracing VVOS's Cash & Equivalents over 5 years: stood at $3.5 million in 2022, then tumbled by 53.31% to $1.6 million in 2023, then soared by 281.01% to $6.3 million in 2024, then plunged by 67.59% to $2.0 million in 2025, then climbed by 3.5% to $2.1 million in 2026.
• Per Business Quant, the three latest VVOS Cash & Equivalents figures stand at $2.1 million (Q1 2026), $2.0 million (Q4 2025), and $3.1 million (Q3 2025).

Peer Comparison